NCT04405401: SUPPRESS-NSCLC

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Recruiting now Phase 2 Last updated 12 December 2023

What this trial tests

Phase 2 trial testing SABR in Lung Cancer Metastatic in 68 participants. Currently enrolling.

Timeline

5 January 2021

Primary endpoint
1 July 2025

1 July 2027

Quick facts

Lead sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	68
Start date	5 January 2021
Primary completion	1 July 2025
Estimated completion	1 July 2027
Sites	1 location across Canada

Drugs / interventions tested

• SABR
• Standard of care

Conditions studied

• Lung Cancer Metastatic — all drugs for Lung Cancer Metastatic →

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

18 and older, any sex, with Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.
   Desai A, Lovly CM. · · 2023 · cited 32× · PMID 37057106 · DOI 10.21037/tlcr-22-708
2. Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives.
   Kinj R, Muggeo E, Schiappacasse L, Bourhis J, et al · · 2022 · cited 22× · PMID 35267460 · DOI 10.3390/cancers14051152
3. Oligometastatic Head and Neck Cancer: Challenges and Perspectives.
   Bahig H, Huang SH, O'Sullivan B. · · 2022 · cited 19× · PMID 36010888 · DOI 10.3390/cancers14163894
4. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
   Prelaj A, Pircher CC, Massa G, Martelli V, et al · · 2021 · cited 15× · PMID 33803958 · DOI 10.3390/cancers13061300
5. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.
   Remon J, Menis J, Levy A, De Ruysscher DKM, et al · · 2021 · cited 14× · PMID 34430382 · DOI 10.21037/tlcr-20-1065
6. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
   Xuzhang W, Huang H, Yu Y, Shen L, et al · · 2023 · cited 11× · PMID 36895853 · DOI 10.1177/17588359231156387
7. Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials.
   Baydoun A, Lee VL, Biswas T. · · 2022 · cited 11× · PMID 36358757 · DOI 10.3390/cancers14215339
8. <b>S</b>tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC).
   Bahig H, Tonneau M, Blais N, Wong P, et al · · 2022 · cited 11× · PMID 35243022 · DOI 10.1016/j.ctro.2021.12.008